Efficacy of Ustekinumab in Patients with Moderate to Severe Crohn's Disease and Active Perianal Fistulas: A Clinical Evaluation

The primary objective of the study is to evaluate the efficacy of **Ustekinumab** in patients with moderate to severe **Crohn's disease** who present with at least one active perianal fistula track. This is clinically relevant as perianal fistulas are a common and challenging complication of Crohn's disease, often leading to significant morbidity. Effective management of these fistulas can improve patient outcomes and quality of life.

The clinical trial involves **patients with moderate to severe Crohn's disease** who have at least one active perianal fistula track. The study population includes both male and female participants, with an age range of 18 to 65 years. The sponsor has not provided information regarding the total number of participants. The trial population was selected without targeting any vulnerable groups. Participants' general health status is characterized by the presence of the specified medical condition, and no specific lifestyle considerations such as diet or physical activity have been highlighted. The sponsor has not disclosed detailed inclusion or exclusion criteria for this study.

The clinical trial is designed to evaluate the efficacy and safety of a treatment in patients with **moderate to severe Crohn's disease** who have at least one active perianal fistula track. The study is structured as a randomized, double-blind, controlled trial, ensuring that neither the participants nor the investigators know which treatment the participants are receiving, thus minimizing bias. The trial commenced on November 16, 2020, and is projected to conclude by December 31, 2025, encompassing a total duration of approximately five years.

Participants will undergo a series of study visits, beginning with an inclusion (screening) visit to assess eligibility based on predefined criteria. This initial visit will involve a comprehensive evaluation of the participant's medical history and current health status. Following successful screening, participants will be randomly assigned to either the treatment or control group. Throughout the trial, participants will attend regular follow-up visits, which will include assessments of treatment efficacy, monitoring of any adverse events, and adjustments to the treatment regimen as necessary. The end-of-study visit will mark the conclusion of the participant's involvement, during which final evaluations will be conducted to gather data on the long-term effects of the treatment.

The expected length of participant involvement in the trial is contingent upon the study's timeline, with individual participation potentially lasting several months to years, depending on the specific protocol requirements. Conditions that may lead to early termination from the study include the occurrence of significant adverse events, non-compliance with study procedures, or withdrawal of consent by the participant. The trial is conducted in accordance with ethical standards and regulatory requirements, ensuring the safety and well-being of all participants throughout the study duration.

The clinical trial involves the administration of an **experimental medication**. However, specific details regarding the name, pharmaceutical form, dosage, route, and frequency of administration of the experimental medication are not provided in the available data. The trial documentation does not specify whether the medication is a paediatric formulation or if it has orphan drug status. Additionally, there is no information on the maximum daily dose, total dose, or treatment period for the experimental medication.

In addition to the experimental medication, the trial may include the use of **non-experimental treatments** such as standard-of-care therapy, placebo, or comparator treatment. However, the data does not provide explicit details about these treatments. Information regarding the administration, dosing schedules, and participant compliance monitoring for these non-experimental treatments is also not available in the provided data.

The clinical trial is designed to assess efficacy through a structured evaluation process. The trial is categorized under phase 6, indicating a specific stage in the clinical research process. The estimated recruitment start date for the trial was November 16, 2020, with an anticipated end date of December 31, 2025. Although specific efficacy parameters such as primary or secondary endpoints are not detailed, the trial will likely involve systematic data collection and analysis to determine the effectiveness of the intervention. The trial's phase and timeline suggest a comprehensive approach to evaluating the intervention's impact on the targeted medical condition. The absence of detailed endpoints implies that efficacy assessments will be aligned with standard clinical trial practices, potentially involving validated scales, laboratory tests, or patient-reported outcomes, measured at predetermined intervals throughout the trial duration.